- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Terry Hyslop, PhD
Professor of Biostatistics and Bioinformatics
Director of Biostatistics, Duke Cancer Institute
Durham, North Carolina
Seeking to identify biomarkers from clinical trial samples to inform strategies to reduce morbidity and mortality from breast cancer.
Analyses of clinical trial data is conducted to identify biomarkers of drug resistance in triple-negative breast cancer (TNBC).
These studies will help to improve treatment for patients with TNBC by identifying predictive factors of response to therapy.
The National Cancer Institute-designated Alliance for Clinical Trials in Oncology (Alliance) has a long and successful history of conducting clinical trials in the adjuvant and metastatic setting that aim to reduce morbidity and mortality from breast cancer. BCRF has provided critical support for the molecular analysis of tumor specimens from these clinical trials. These efforts are critically important for the development of biomarkers that can predict risk of recurrence, as well as the identification of new treatment for drug-resistant tumors.
Dr. Hyslop continues her work with BCRF colleagues Monica Bertagnolli and Deanna Kroetz to conduct analyses within phase III trials of the Alliance. In a study of advanced estrogen receptor (ER) positive breast cancers, the investigators will identify subgroups of patients who may benefit from anti-estrogen therapy alone versus the addition of a second targeted therapy, bevacizumab.
In a separate analysis of four recently completed breast cancer studies, they hope to identify genetic factors responsible for peripheral neuropathy, a major side effect of a commonly used class of chemotherapy drugs called taxanes.
Terry Hyslop is Professor of Biostatistics and Bioinformatics at Duke University and Director of Biostatistics for the Duke Cancer Institute. Dr. Hyslop has over 20 years of experience as a biostatistician, with methodological interests in the measurement of biomarkers and models of initiation and prognosis in cancer. Her collaborative work in breast cancer includes multi-center biomarker studies, clinical trials, and correlative studies in clinical trials both at Duke and nationally with the Alliance Clinical Trials Group. Dr. Hyslop’s research focuses on using latent class mixture models to elucidate disparities in cancer outcomes by linking biomarker and genomic information with lifestyle and other exposures, with the goal of identifying modifiable factors.